K. Abu Jabal, Hila Ben-Amram, K. Beiruti, Yunis Batheesh, Christian Sussan, S. Zarka, M. Edelstein
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2021
The BNT162b2 mRNA COVID-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We describe immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, ethnicity, sex and prior COVID-19 infection. Immunogenicity was similar by ethnicity and sex but decreased with age. Those with prior infection had antibody titres one magnitude order higher than naïve individuals regardless of the presence of detectable IgG antibodies pre-vaccination.
Cited by 77 publications.
Field of study: Medicine